Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (684)	2/21/2000 9:16:00 PM
From: stockman_scott	Respond to of 52153

IMO, BLSI is a very promising biotech firm that actually still has 'a rational valuation' <VBG>....Here is the latest release from the company... biz.yahoo.com <<Friday February 18, 9:36 am Eastern Time Company Press Release Buy Rating On Boston Life Sciences Reiterated by H.C. Wainwright & Co. BOSTON--(BW HealthWire)--Feb. 18, 2000--Boston Life Sciences, Inc. (NASDAQ:BLSI - news) announced that H.C. Wainwright & Co. Healthcare Technology analyst Ronald Opel reiterated his buy rating on Boston Life Sciences in a First Call notice released yesterday. The report was issued in response to the Company's announcement of preliminary results of a primate study which demonstrated that the Company's lead therapeutic compound, O-1369, significantly improved the symptoms of experimental Parkinson's Disease (PD). ''We believe that this compound may represent a fresh approach to the effective treatment of PD. The results of the studies with the lead compound demonstrated impressive Parkinson's disease movement improvement,'' commented Opel. The research release also noted that the Phase III trial of BLSI's Altropane as a diagnostic agent for the early detection of PD is on track for completion at the end of the current quarter. H. C. Wainwright & Co., Inc. founded in 1868 and based in Boston, is a leading source of high-quality equity research, investment banking, asset management consulting, retail and institutional securities brokerage, and other financial advisory services. The firm's strong background in equity research enables it to provide institutional and individual clients with accurate and up-to-date investment information and counsel. BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune diseases, and central nervous system disorders. BLSI's products in development include: Altropane, a radioimaging agent for the diagnosis of Parkinson's Disease and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; fusion toxins for the treatment of cancer and multiple sclerosis; novel therapies for the treatment of Parkinson's Disease and ADHD and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, the market size for the Company's products and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties and actual results may vary materially from these statements. Factors that may affect future results include: regulatory decisions, results of scientific data from clinical trials; delays in the regulatory or development processes; the ability to obtain intellectual property protection, the outcome of discussions with potential partners, the availability and adequacy of financial resources, and market acceptance of the Company's products.>> Best Regards, Scott